BRPI0910461B8 - hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso - Google Patents

hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso

Info

Publication number
BRPI0910461B8
BRPI0910461B8 BRPI0910461A BRPI0910461A BRPI0910461B8 BR PI0910461 B8 BRPI0910461 B8 BR PI0910461B8 BR PI0910461 A BRPI0910461 A BR PI0910461A BR PI0910461 A BRPI0910461 A BR PI0910461A BR PI0910461 B8 BRPI0910461 B8 BR PI0910461B8
Authority
BR
Brazil
Prior art keywords
production method
stimulating hormone
follicle stimulating
pharmaceutical composition
recombinant follicle
Prior art date
Application number
BRPI0910461A
Other languages
English (en)
Portuguese (pt)
Inventor
Plaksin Daniel
Cottingham Ian
Boyd White Richard
Original Assignee
Ferring Int Center Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0910461(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Int Center Sa filed Critical Ferring Int Center Sa
Publication of BRPI0910461A2 publication Critical patent/BRPI0910461A2/pt
Publication of BRPI0910461A8 publication Critical patent/BRPI0910461A8/pt
Publication of BRPI0910461B1 publication Critical patent/BRPI0910461B1/pt
Publication of BRPI0910461B8 publication Critical patent/BRPI0910461B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1081Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0910461A 2008-04-16 2009-04-16 hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso BRPI0910461B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
US61/045,424 2008-04-16
EP08251528.9 2008-04-25
EP08251528 2008-04-25
PCT/GB2009/000978 WO2009127826A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (4)

Publication Number Publication Date
BRPI0910461A2 BRPI0910461A2 (pt) 2018-03-27
BRPI0910461A8 BRPI0910461A8 (pt) 2018-10-16
BRPI0910461B1 BRPI0910461B1 (pt) 2021-02-23
BRPI0910461B8 true BRPI0910461B8 (pt) 2021-05-25

Family

ID=39717519

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910461A BRPI0910461B8 (pt) 2008-04-16 2009-04-16 hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso

Country Status (29)

Country Link
US (6) US8951967B2 (OSRAM)
EP (7) EP3144318B1 (OSRAM)
JP (7) JP2011519359A (OSRAM)
KR (5) KR20170110741A (OSRAM)
CN (3) CN102066414A (OSRAM)
AR (1) AR071479A1 (OSRAM)
AU (5) AU2009237479B2 (OSRAM)
BR (1) BRPI0910461B8 (OSRAM)
CA (1) CA2725257A1 (OSRAM)
CY (1) CY1115413T1 (OSRAM)
DK (6) DK3045471T3 (OSRAM)
ES (5) ES2610277T3 (OSRAM)
FI (4) FI3098234T3 (OSRAM)
FR (3) FR17C1020I2 (OSRAM)
HR (5) HRP20241187T1 (OSRAM)
HU (9) HUE068565T2 (OSRAM)
IL (2) IL208538A (OSRAM)
LT (8) LT3045471T (OSRAM)
MX (3) MX355457B (OSRAM)
NO (4) NO2017025I1 (OSRAM)
NZ (1) NZ588381A (OSRAM)
PL (6) PL2808340T3 (OSRAM)
PT (6) PT2268666E (OSRAM)
RU (3) RU2537268C2 (OSRAM)
SA (1) SA109300228B1 (OSRAM)
SI (6) SI2808340T1 (OSRAM)
TW (1) TWI488640B (OSRAM)
WO (1) WO2009127826A1 (OSRAM)
ZA (1) ZA201007373B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
RS54214B2 (sr) 2010-09-29 2024-02-29 Ferring Bv Smeša za upotrebu u lečenju infertiliteta
WO2012050175A1 (ja) 2010-10-15 2012-04-19 日本ケミカルリサーチ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
CN103619358B (zh) * 2011-03-31 2017-02-15 辉凌公司 药物制剂
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
JP6279466B2 (ja) * 2012-04-27 2018-02-14 Jcrファーマ株式会社 新規な発現ベクター
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Jcrファーマ株式会社 ウリジンとn−アセチル−d−マンノサミンとを含有する培地
CN107429237B (zh) * 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 Cmp依赖性的唾液酸酶活性
PL3662925T3 (pl) 2015-04-17 2021-10-25 Ferring B.V. Kompozycja zawierająca FSH do leczenia niepłodności
JP6845813B2 (ja) 2015-06-26 2021-03-24 フェリング ベスローテン フェンノートシャップ 精製および/またはウイルス不活性化の方法
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
DK3973982T3 (da) 2017-09-01 2024-09-23 Ferring Bv Sammensætning til kontrolleret ovariestimulation
PL3787667T3 (pl) 2018-04-30 2025-07-28 Ferring B.V. Kompozycja do kontrolowanej stymulacji jajników
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
JP2025511129A (ja) 2022-04-01 2025-04-15 フェリング ベスローテン フェンノートシャップ 不妊症の治療のための混合プロトコル
US20250333466A1 (en) 2022-05-26 2025-10-30 Ferring B.V. Compositions and methods for treatment of infertility in males
US20250367262A1 (en) 2022-07-08 2025-12-04 Ferring B.V. Compositions and methods for intrauterine insemination (iui)
AR133300A1 (es) 2023-07-20 2025-09-17 Ferring Bv Micropartículas cargadas con fármaco de liberación prolongada

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
DE69823046T2 (de) 1997-01-16 2005-03-31 Neose Technologies, Inc. Praktische in vitro sialylierung von rekombinanten glykpproteinen
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
BR0010709B1 (pt) 1999-05-07 2011-11-29 uso de lh para a produção de um medicamento para induzir a paucifoliculogênese ou unifoliculogênese em mulheres anovulatórias.
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
DE60212425T2 (de) * 2001-10-22 2006-11-09 Applied Research Systems Ars Holding N.V. Fsh-zusammensetzungen mit hohem sialylierungsgrad und deren verwendung zur herstellung von arzneimitteln
CN100347306C (zh) 2001-10-29 2007-11-07 克鲁塞尔荷兰公司 生产具有预定的翻译后修饰的蛋白质的方法和手段
CN100547069C (zh) 2001-12-07 2009-10-07 克鲁塞尔荷兰公司 病毒、病毒分离物和疫苗的生产
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2005056760A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
ES2350298T3 (es) 2004-02-04 2011-01-20 Centre National De La Recherche Scientifique Procedimiento para el cribado de anticuerpos específicos de glicoforma.
JP4913604B2 (ja) 2004-02-13 2012-04-11 グリコトープ ゲーエムベーハー 高活性糖タンパク質−製造条件、及びその効率的製造方法
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
EP2600809B1 (en) 2010-08-03 2015-02-25 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
RS54214B2 (sr) 2010-09-29 2024-02-29 Ferring Bv Smeša za upotrebu u lečenju infertiliteta
CN103619358B (zh) 2011-03-31 2017-02-15 辉凌公司 药物制剂
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
SG11201608132UA (en) 2014-04-18 2016-11-29 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
RU2682270C2 (ru) 2019-03-18
TW200948378A (en) 2009-12-01
LTPA2025525I1 (OSRAM) 2025-07-25
PT3144318T (pt) 2020-11-04
EP3098234B1 (en) 2024-07-31
LT4015527T (lt) 2025-04-10
AU2017225020B2 (en) 2019-11-14
NZ588381A (en) 2012-05-25
BRPI0910461A2 (pt) 2018-03-27
EP2268666B1 (en) 2014-03-12
PT4015527T (pt) 2025-04-10
PT2808340T (pt) 2016-11-21
PT3098234T (pt) 2024-10-21
US20210332099A1 (en) 2021-10-28
CN105906703A (zh) 2016-08-31
HUS1700025I1 (hu) 2017-06-28
FR25C1003I1 (fr) 2025-02-28
RU2010141908A (ru) 2012-05-27
LTPA2017018I1 (lt) 2017-06-26
PT2268666E (pt) 2014-06-25
NO2025032I1 (no) 2025-07-14
EP2268666A1 (en) 2011-01-05
HUE030652T2 (en) 2017-05-29
JP2018021037A (ja) 2018-02-08
KR20160056960A (ko) 2016-05-20
JP2024038000A (ja) 2024-03-19
LT3045471T (lt) 2017-07-10
EP3098234A1 (en) 2016-11-30
HRP20241187T1 (hr) 2024-12-06
MX348622B (es) 2017-06-22
SI3098234T1 (sl) 2024-10-30
US20160347811A1 (en) 2016-12-01
AU2009237479A1 (en) 2009-10-22
ES2629392T3 (es) 2017-08-09
FR17C1020I1 (OSRAM) 2020-04-10
HUE033830T2 (en) 2018-01-29
LTPA2017029I1 (lt) 2017-10-10
PL2808340T3 (pl) 2017-02-28
HUS1700036I1 (hu) 2017-10-30
KR20190092608A (ko) 2019-08-07
CN105906702A (zh) 2016-08-31
KR20110005863A (ko) 2011-01-19
LT3098234T (lt) 2024-09-10
EP4015527A1 (en) 2022-06-22
ES2468318T3 (es) 2014-06-16
FIC20250003I1 (fi) 2025-01-15
AU2009237479B2 (en) 2014-05-15
US20180079794A1 (en) 2018-03-22
FI3098234T3 (fi) 2024-10-31
HUS2500029I1 (hu) 2025-07-28
HK1146284A1 (en) 2011-05-20
PL3098234T3 (pl) 2025-01-07
EP2722339A1 (en) 2014-04-23
DK2808340T3 (en) 2016-12-05
DK3098234T3 (da) 2024-10-21
CA2725257A1 (en) 2009-10-22
FR17C1020I2 (fr) 2020-04-10
DK3045471T3 (en) 2017-06-26
JP6762916B2 (ja) 2020-09-30
EP3045471B1 (en) 2017-03-29
SI2268666T1 (sl) 2014-07-31
SI4015527T1 (sl) 2025-05-30
AU2014203277B2 (en) 2017-04-06
RU2745557C1 (ru) 2021-03-29
JP2022031652A (ja) 2022-02-22
AU2017225020A1 (en) 2017-09-28
JP6486310B2 (ja) 2019-03-20
JP7316905B2 (ja) 2023-07-28
LT2808340T (lt) 2016-11-10
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
NO2025006I1 (no) 2025-01-16
AU2014203277C1 (en) 2017-07-27
PL3144318T3 (pl) 2021-02-08
SI3144318T1 (sl) 2020-12-31
EP2808340B1 (en) 2016-08-17
AU2017204259A1 (en) 2017-07-20
US9771407B2 (en) 2017-09-26
RU2745557C3 (ru) 2021-12-10
HRP20161520T1 (hr) 2016-12-30
PL2268666T3 (pl) 2014-08-29
NO2017050I1 (no) 2017-09-28
ES2989729T3 (es) 2024-11-27
EP2808340A1 (en) 2014-12-03
AR071479A1 (es) 2010-06-23
BRPI0910461B1 (pt) 2021-02-23
SA109300228B1 (ar) 2014-04-08
IL230571A (en) 2015-11-30
WO2009127826A1 (en) 2009-10-22
BRPI0910461A8 (pt) 2018-10-16
DK4015527T3 (da) 2025-04-14
PT3045471T (pt) 2017-06-14
KR20170110741A (ko) 2017-10-11
JP2020040956A (ja) 2020-03-19
HUS2500008I1 (hu) 2025-02-28
SI2808340T1 (sl) 2016-12-30
US11952407B2 (en) 2024-04-09
AU2017204258B2 (en) 2017-08-17
EP4015527B1 (en) 2025-01-22
US20150065695A1 (en) 2015-03-05
AU2017204259B2 (en) 2017-08-17
CN102066414A (zh) 2011-05-18
RU2014141994A (ru) 2016-05-10
DK3144318T3 (da) 2020-12-07
HRP20170958T1 (hr) 2017-09-22
HUE068565T2 (hu) 2025-01-28
EP3045471A1 (en) 2016-07-20
HUS1700024I1 (hu) 2017-06-28
SI3045471T1 (sl) 2017-07-31
HRP20250313T1 (hr) 2025-05-09
HUE030652T4 (en) 2017-09-28
RU2014141994A3 (OSRAM) 2018-05-28
CY1115413T1 (el) 2017-01-04
US20240327487A1 (en) 2024-10-03
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
ES3023526T3 (en) 2025-06-02
IL208538A (en) 2014-03-31
LTPA2025505I1 (OSRAM) 2025-02-10
RU2537268C2 (ru) 2014-12-27
IL208538A0 (en) 2010-12-30
US10995128B2 (en) 2021-05-04
JP2015120696A (ja) 2015-07-02
MX355457B (es) 2018-04-19
US8951967B2 (en) 2015-02-10
TWI488640B (zh) 2015-06-21
EP3144318A1 (en) 2017-03-22
US20110105398A1 (en) 2011-05-05
JP2011519359A (ja) 2011-07-07
JP2017060476A (ja) 2017-03-30
EP3144318B1 (en) 2020-09-23
AU2014203277A1 (en) 2014-07-24
US9546204B2 (en) 2017-01-17
ZA201007373B (en) 2011-06-29
DK2268666T3 (da) 2014-05-12
KR101622944B1 (ko) 2016-05-23
FR25C1025I1 (fr) 2025-09-19
PL3045471T3 (pl) 2017-10-31
NO2017025I1 (no) 2017-06-06
KR102108377B1 (ko) 2020-05-08
HUE071059T2 (hu) 2025-07-28
KR20180095140A (ko) 2018-08-24
FI4015527T3 (fi) 2025-04-29
AU2017204258A1 (en) 2017-07-20
FIC20250025I1 (fi) 2025-07-11
HK1199039A1 (en) 2015-06-19

Similar Documents

Publication Publication Date Title
BRPI0910461B8 (pt) hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso
BRPI0805826B8 (pt) compostos espiro-substituídos, composição farmacêutica e uso
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
WO2011144673A3 (en) Long - acting formulations of insulins
BR112015014760A2 (pt) complexo de zinco-aminoácido com cisteína
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
BR112015032559A8 (pt) cerâmica odontológica de zircônia, artigo odontológico, e seu método de fabricação
NZ586588A (en) Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
CL2008003537A1 (es) Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alergica, inmunologica o inflamatoria o dolor.
ECSP034772A (es) Antagonistas de mch y su uso en el tratamiento de obesidad
WO2012127501A3 (en) Composition for improving endometrial thickness during ovarian stimulation
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
CR10092A (es) Nuevos derivados de furopirimidina aciclicos sustituidos y su uso
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
BR112015032200A2 (pt) conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
BRPI1012666B8 (pt) cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso
BR112022012063A2 (pt) Comprimidos de edoxabana
CL2008003546A1 (es) Compuestos derivados de piridina; procedimiento de preparacion; composicion farmaceutica de dichos compuestos; y uso en el tratamiento y/o profilaxis de la diabetes mellitus tipo i y/o tipo ii.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF